drugset / Trial / NCT07179900
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This project is a prospective, open-label, randomized controlled clinical study. It plans to enroll 60 patients with unresectable HCC and no distant metastasis, randomly assigned to the experimental group and the control group, with 30 cases in each group. The experimental group was treated with radiotherapy combined with immunotherapy and Bevacizumab, while the control group was treated with immunotherapy and Bevacizumab. The efficacy of the patients and the conversion rate to surgery were evaluated.
Timeline
- Start
- 2025-12
- Primary completion
- 2027-12
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QL1706 | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | — |
| Background | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |